FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna)

Why It Matters

The restriction could limit use of a widely prescribed renin inhibitor, prompting clinicians to reassess combination therapy for hypertensive patients with diabetes or kidney disease, and may affect market share for aliskiren products.

Key Takeaways

• FDA bans aliskiren with ACEI/ARB in diabetic patients.
• Warning added for renal impairment (GFR <60 mL/min).
• ALTITUDE trial showed increased renal, hypotension, hyperkalemia risks.
• 22% of aliskiren users also took ACEI/ARB with diabetes.
• Novartis to discontinue Valturna marketing after July 2012.

Pulse Analysis

Aliskiren, marketed under names such as Tekturna and Valturna, is a direct renin inhibitor that lowers blood pressure by blocking the first step of the renin‑angiotensin‑aldosterone system. Prior to the FDA’s April 2012 safety communication, the drug was prescribed to millions of Americans, often alongside ACE inhibitors or angiotensin‑receptor blockers to achieve tighter control of hypertension. The new labeling mandates a contraindication for diabetic patients and a warning for those with moderate to severe renal impairment, reflecting growing concerns about overlapping mechanisms and additive adverse effects.

The FDA’s decision was driven by interim data from the ALTITUDE trial, a large post‑approval study that was halted early after a median 27‑month follow‑up. Patients receiving aliskiren in addition to an ACEI or ARB experienced higher incidences of serious renal events (4.7% vs. 3.3% on placebo), hypotension, and hyperkalemia, with a modest, non‑definitive rise in stroke and mortality rates. These findings underscore the importance of vigilant monitoring when combining agents that act on the same hormonal pathway, especially in high‑risk populations such as those with type‑2 diabetes and existing kidney disease.

For clinicians, the communication translates into immediate prescribing changes: avoid aliskiren‑based combos in diabetic patients, reassess therapy for anyone with a glomerular filtration rate below 60 mL/min, and consider alternative antihypertensives. From a commercial perspective, Novartis’s decision to withdraw Valturna after July 2012 signals a potential contraction of the aliskiren market, prompting competitors to highlight safety profiles of their own renin‑angiotensin blockers. Ongoing surveillance of final ALTITUDE results and other aliskiren studies will further shape regulatory guidance and could influence future formulary decisions across health systems.